Viagra vs Vardenafil (Levitra/Staxyn): Cost and Access Head-to-Head

What Are Sildenafil and Vardenafil, and How Do They Work?

Both sildenafil and vardenafil block the enzyme phosphodiesterase type 5 (PDE5), which breaks down cyclic GMP in penile smooth muscle. Higher cyclic GMP levels allow smooth muscle relaxation and increased blood flow during sexual stimulation. Neither drug produces an erection without arousal.

The PDE5 Inhibitor Mechanism

Goldstein et al. Published the landmark 1998 NEJM trial establishing sildenafil as the first effective oral treatment for erectile dysfunction across 532 men, demonstrating dose-dependent improvements in erections at 25, 50, and 100 mg compared with placebo 1. That study set the template for how all PDE5 inhibitors would be evaluated.

Vardenafil received FDA approval in August 2003, roughly five years after sildenafil. In biochemical binding assays, vardenafil shows approximately 10-fold higher PDE5 selectivity than sildenafil, but that laboratory difference does not translate cleanly into a clinically meaningful efficacy advantage for the average patient 2.

Staxyn: The Orally Disintegrating Formulation

Staxyn is a 10 mg orally disintegrating tablet (ODT) of vardenafil. It dissolves on the tongue without water, which can be useful for men who prefer discrete dosing or have swallowing difficulties. Bioavailability of the ODT formulation differs slightly from the standard film-coated Levitra tablet, so the two are not substitutable on a milligram-for-milligram basis.

Efficacy Comparison: Does One Drug Work Better?

Head-to-head trials between sildenafil and vardenafil show broadly similar success rates in the general ED population. Response rates for both agents in randomized controlled trials typically fall between 65% and 80% on standard IIEF (International Index of Erectile Function) measures, with no consistently superior agent identified across multiple studies 2.

Efficacy in Diabetic Erectile Dysfunction

Porst et al. (Int J Impot Res, 2003) specifically evaluated vardenafil in men with diabetic ED, a population historically difficult to treat because autonomic neuropathy and vascular disease reduce nitric oxide signaling. In that trial, vardenafil 10 mg and 20 mg produced statistically significant improvements in IIEF erectile function domain scores versus placebo (P<0.001), with successful intercourse rates of 57% (10 mg) and 72% (20 mg) compared with 28% for placebo 2. Sildenafil also carries strong evidence in diabetic populations from separate trials, so neither drug holds a definitive edge in this subgroup.

Onset and Duration: Practical Differences

Both drugs reach peak plasma concentration within 30 to 60 minutes when taken on an empty stomach. A fatty meal delays sildenafil absorption more than vardenafil absorption, a practical difference worth noting for men who often take the drug after dinner. Duration of action is comparable at roughly 4 to 6 hours for both agents. Tadalafil (Cialis) remains the outlier in the PDE5 class for duration at 17 to 36 hours, but that is outside the scope of this comparison.

Selectivity and Side Effects

Vardenafil's higher PDE5 selectivity over PDE6 (expressed in the retina) may produce fewer visual disturbances, such as the blue-tinge effect some men notice with sildenafil. Both agents can cause headache (10 to 16%), flushing (10 to 11%), nasal congestion, and dyspepsia at standard doses 1. Vardenafil carries a QTc prolongation warning on its label, which sildenafil does not, making it less suitable for men taking Class IA or Class III antiarrhythmics.

Cost Comparison: The Real Deciding Factor for Most Men

Price is where these two drugs diverge most sharply in 2025. Generic sildenafil has been available in the United States since 2017 and benefits from intense manufacturer competition. Generic vardenafil reached the US market later and with fewer competing manufacturers, keeping prices higher.

Sildenafil Pricing

• Brand Viagra (100 mg): $70 to $100 per tablet without insurance at major retail pharmacies.
• Generic sildenafil (100 mg): $4 to $15 per tablet at retail pharmacies without discount.
• Generic sildenafil with GoodRx or similar coupon: As low as $1 to $3 per tablet for a supply of 30 tablets.
• Telehealth / mail-order pharmacy (e.g., HealthRX): Compounded or generic sildenafil 20 mg tablets (often used off-label in stacks of 2 to 4) can drop per-dose cost further.

The FDA maintains a current list of approved sildenafil generics at accessdata.fda.gov, confirming more than a dozen active ANDAs (abbreviated new drug applications) for sildenafil citrate, which sustains price competition 3.

Vardenafil Pricing

• Brand Levitra (10 mg): $70 to $90 per tablet without insurance.
• Generic vardenafil (10 mg): $10 to $25 per tablet at retail without discount.
• Generic vardenafil with GoodRx coupon: $3 to $8 per tablet depending on pharmacy and supply size.
• Staxyn (10 mg ODT): Often more expensive than standard vardenafil tablets; generic ODT vardenafil availability is limited.

Insurance Coverage

Most commercial insurance plans, including Medicare Part D, classify PDE5 inhibitors as lifestyle medications and exclude them from standard formularies. The Centers for Medicare and Medicaid Services (CMS) does not require Part D plans to cover erectile dysfunction drugs under standard benefit rules, meaning cash price matters for the majority of patients 4. Some employer-sponsored plans do include one or both agents, and a small number of plans prefer generic sildenafil over vardenafil due to lower negotiated rates.

The Bottom Line on Cost

Generic sildenafil wins on price by a wide margin in nearly every pharmacy channel available today. A 30-tablet supply of generic sildenafil 100 mg with a discount coupon can cost under $50, while the same supply of generic vardenafil 10 mg typically runs $90 to $150 at the same pharmacies.

Access: Prescribing, Telehealth, and Availability

Prescription Requirements

Both sildenafil and vardenafil are Schedule-unscheduled prescription-only medications in the United States. A licensed provider must issue a valid prescription before a pharmacy can dispense either drug. The FDA has not approved an OTC version of either agent as of July 2025 3.

Telehealth Access

The expansion of telehealth under the COVID-19 public health emergency and subsequent regulatory extensions changed how men access ED medications. Platforms can now prescribe sildenafil and vardenafil via asynchronous or synchronous visits in most US states. Sildenafil tends to be the default prescription issued by telehealth platforms because the lower cost improves patient adherence and refill rates.

Compounding Considerations

FDA-registered 503A compounding pharmacies may compound sildenafil into alternative formulations (oral solutions, customized doses) for patients with documented clinical need. Vardenafil compounding is less common in practice. The FDA regulates compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act 3.

International Access

In many countries, including the United Kingdom and Canada, sildenafil 50 mg (branded as Viagra Connect) is available OTC without a prescription. Vardenafil does not have equivalent OTC approval in any major market as of 2025. For US patients traveling abroad, familiarity with the OTC sildenafil option can be practically useful, though formulations and labeling may differ.

Safety Profile and Contraindications

Nitrate Contraindication

Both drugs are absolutely contraindicated with all nitrate formulations, including nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, and recreational amyl nitrite ("poppers"). Concurrent use risks life-threatening hypotension by additive cGMP accumulation in vascular smooth muscle 1. The ACC/AHA guidelines on stable ischemic heart disease specify that PDE5 inhibitors should not be used within 24 hours of short-acting nitrates and 48 hours of long-acting nitrates 5.

Cardiovascular Considerations

Sexual activity itself carries a low but real cardiac metabolic demand of roughly 3 to 5 METs. The Princeton Consensus III guidelines (2012) stratify men into low, intermediate, and high cardiovascular risk categories before PDE5 inhibitor prescribing 5. Men in the low-risk category (stable, well-controlled hypertension; no symptoms with mild exertion) can generally receive a prescription for either agent without additional cardiac workup.

Vardenafil-Specific Warning: QTc Prolongation

The prescribing information for Levitra includes a warning about dose-dependent QTc prolongation. In pharmacodynamic studies, vardenafil 10 mg prolonged the QTc interval by approximately 8 ms and the 80 mg supratherapeutic dose by 10 ms. This warning is not present on sildenafil's label. Men taking Class IA antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol) should not use vardenafil 2.

Drug Interactions: Alpha-Blockers

Both agents can produce additive hypotension with alpha-blockers (terazosin, doxazosin, tamsulosin) used for benign prostatic hyperplasia. The FDA label for both drugs recommends initiating at the lowest dose and allowing a 4-hour separation between doses when co-prescribing with alpha-blockers 3.

Which Patient Fits Which Drug?

The decision framework below reflects clinical patterns observed across the HealthRX prescribing network and is consistent with published pharmacology. No single algorithm fits every patient, but the following categories help clinicians and patients start the conversation.

Choose Sildenafil When:

• Cost is a primary concern. Generic sildenafil at $1 to $3 per dose with coupon is difficult to beat.
• The patient eats lightly before sex. Sildenafil's absorption is less affected on a relatively empty stomach, producing consistent onset.
• Insurance covers it. When a plan covers sildenafil generics, out-of-pocket costs drop to $0 to $10 per month.
• The patient has prior success or familiarity. Switching a patient who tolerates and responds well to sildenafil provides no clinical benefit.

Choose Vardenafil When:

• Sildenafil causes visual side effects. The blue-tinge and photosensitivity reported with sildenafil, mediated by mild PDE6 inhibition in the retina, are less common with vardenafil.
• The patient wants an ODT option. Staxyn dissolves on the tongue in about 15 seconds. Discretion or dysphagia may make this preferable.
• High-fat meals are the norm. Vardenafil's absorption is less affected by fat than sildenafil's, giving more predictable onset in men who take the pill after a large dinner.
• The patient has tried sildenafil and found onset too slow. Some men subjectively report slightly faster onset with vardenafil, though pharmacokinetic data show only modest differences.

Patients Who Should Avoid Vardenafil

Men on Class IA or III antiarrhythmics should not use vardenafil due to QTc concerns. Sildenafil or tadalafil (after appropriate cardiac evaluation) may be safer alternatives for this subgroup.

Dosing Reference

Sildenafil Standard Dosing

The approved starting dose for most men is 50 mg taken 30 to 60 minutes before sexual activity. The dose may be increased to 100 mg or decreased to 25 mg based on response and tolerability. Patients with significant hepatic impairment or severe renal impairment (<30 mL/min creatinine clearance) should start at 25 mg. The maximum recommended frequency is once daily 1.

Vardenafil Standard Dosing

The starting dose of Levitra is 10 mg taken 25 to 60 minutes before activity, with an allowable range of 5 to 20 mg. Staxyn is available only as a fixed 10 mg ODT. Men 65 or older should start at 5 mg of the film-coated tablet. Dose adjustment is required for moderate hepatic impairment (Child-Pugh B): maximum 10 mg. Strong CYP3A4 inhibitors such as ritonavir and ketoconazole require significant dose reductions or avoidance 2.

What Published Guidelines Say

The American Urological Association (AUA) 2018 guideline on erectile dysfunction names PDE5 inhibitors as the recommended first-line oral pharmacotherapy for ED, stating: "Phosphodiesterase type 5 inhibitors are effective for the treatment of erectile dysfunction and are recommended as first-line therapy." The guideline does not preferentially endorse one PDE5 inhibitor over another, directing clinicians to individualize based on patient preference, cost, and comorbidities 6.

The American College of Cardiology Foundation and American Heart Association joint 2012 statement on cardiovascular recommendations for men with ED concluded: "PDE5 inhibitors have demonstrated efficacy and an acceptable safety profile in patients with stable cardiovascular disease who are not taking nitrates" 5.

Switching Between Sildenafil and Vardenafil

Men can switch between sildenafil and vardenafil at any time without a washout period, given both agents have half-lives under 5 hours. A prescriber should reassess the indication, adjust dose, and confirm no new contraindications before issuing the new prescription. In practice, the most common reason for switching from sildenafil to vardenafil is visual side effects or food-timing inconvenience. The most common reason for switching back to sildenafil from vardenafil is cost.

No head-to-head crossover trial has definitively shown that switching agents rescues men who failed their first PDE5 inhibitor when proper instructions were followed. Technique matters: taking the pill with food, not waiting for spontaneous arousal, insufficient sexual stimulation, and anxiety about performance all reduce apparent efficacy of any PDE5 inhibitor.